Riskpilot← Back to searchSign inGet full accessMC2 Therapeutics A/S
A/SActiveCVR 29526346Agern Alle 24-26Manufacture of pharmaceutical preparations · NACE 2120Est. 20069 employees
Revenue 2024
DKK 24,5M
-7% vs 2023
EBITDA margin
5.1%
-34% vs 2023
Equity ratio
-339.2%
Financial strength
Net profit 2024
DKK -53M
-27% vs 2023
| Revenue | DKK 24,5M | -7% |
| EBITDA | DKK 1,3M | -34% |
| Net profit | DKK -53M | -27% |
| Total assets | DKK 64,4M | +110% |
| Equity | DKK -218,4M | -33% |
| Employees | 9 | — |
Legal name
MC2 Therapeutics A/S
CVR number
29526346
Legal form
Aktieselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
4. maj 2006
Share capital
DKK 6.611.484
Employees
9 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør eller af den samlede bestyrelse
Company purpose
Selskabets formål er at udøve innovations-, forsknings- og udviklingsaktivitet indenfor medicinal- og sundheds-branchen, og at drive handelsvirksomhed dermed, samt al virksomhed, som efter bestyrelsens skøn har forbindelse hermed, herunder udvikling, køb og salg af immaterielle rettigheder eller medicinske produkter samt at besidde ejerandele i virksomheder, som udøver lignende aktiviteter.
Address
Agern Alle 24-26
Phone
+4520181111
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.245 | 3.532 | 5.586 | 5.411 | 6.842 | 10.252 | 13.340 | 13.678 | 15.938 | 27.734 | 25.008 | 26.355 | 24.493 |
| Staff expenses | -4.840 | -3.911 | -5.476 | -5.182 | -6.548 | -9.799 | -12.403 | -14.068 | -14.706 | -26.007 | -23.156 | -24.445 | -23.237 |
| EBITDA | 405 | -379 | 110 | 229 | 294 | 453 | 937 | -389 | 1.232 | 1.727 | 1.852 | 1.910 | 1.257 |
| Depreciation & amort. | -13 | -1 | -0 | -123 | -134 | -171 | -94 | -216 | -245 | -276 | -225 | -241 | -100 |
| EBIT | 392 | -380 | 110 | 106 | 160 | 282 | 843 | -605 | 987 | 1.452 | 1.628 | 1.670 | 1.157 |
| Net financials | -31.727 | -24.621 | -19.962 | -24.558 | -39.931 | -80.035 | -110.734 | -80.667 | -88.057 | -26.675 | -102.959 | -43.521 | -54.164 |
| Profit before tax | -31.335 | -25.002 | -19.852 | -24.452 | -39.770 | -79.754 | -109.891 | -81.272 | -87.070 | -25.223 | -101.331 | -41.851 | -53.007 |
| Tax | -7 | 5 | -13 | -0 | 370 | -626 | 176 | 129 | -129 | -0 | -0 | -0 | -0 |
| Net profit | -31.328 | -25.007 | -19.840 | -24.452 | -40.140 | -79.128 | -110.067 | -81.401 | -86.941 | -25.223 | -101.331 | -41.851 | -53.007 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 6.806 | 17.205 | 41.061 | 49.136 | 78.630 | 47.188 | 74.367 | 105.728 | 36.145 | 51.603 | 38.592 | 30.589 | 64.386 |
| Equity | -288.904 | 15.928 | 35.388 | 43.362 | 54.375 | 30.873 | 62.254 | 65.832 | 13.930 | -21.098 | -122.650 | -164.534 | -218.391 |
| Long-term debt | 107.391 | 107 | 107 | 107 | 107 | 0 | 0 | 424 | 1.058 | 914 | 157.155 | 190.449 | 270.165 |
| Short-term debt | 187.866 | 1.169 | 5.566 | 1.596 | 3.486 | 6.288 | 2.707 | 30.099 | 11.675 | 71.786 | 4.087 | 4.674 | 12.612 |
| Total debt | 295.256 | 1.276 | 5.673 | 1.703 | 3.593 | 6.288 | 2.707 | 30.523 | 12.733 | 72.700 | 161.242 | 195.123 | 282.777 |
EBITDA margin
5.1%
This company
15.8%
Market median
-68% vs market
20122024
Equity ratio
-339.2%
This company
38.2%
Market median
-988% vs market
20122024
Return on equity
-5300693100.0%
This company
18.4%
Market median
-28808114774% vs market
20122024
Net profit margin
-216.4%
This company
8.1%
Market median
-2772% vs market
20122024
Asset turnover
0.38×
This company
1.12×
Market median
-66% vs market
20122024
Debt / equity
1.29×
This company
0.62×
Market median
-108% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
TA Management | Management | 2025 | — | — |
AM Management | Management | 2006 | — | — |
JJ Founder | Founder | 2006 | — | — |
SS Management | Management | 2006 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2017 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2017 | — | — | |
| Board of Directors | 2017 | — | — | |
| Board of Directors | 2023 | — | — | |
| Chairman | 2017 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Alsmark Invest II ApS | Company | 33.3% | 33.3% | 2023 |
Selskabet af 4. april 2023 ApS | Company | 33.3% | 33.3% | 2023 |
MC2 HOLDING ApS | Company | 15.0% | 15.0% | 2018 |
INVESTERINGSSELSKABET AF 30.4.1992 ApS | Company | 33.3% | 33.3% | 2019 |
| Individual | 33.3% | 33.3% | 2016 | |
HOLDINGSELSKABET J.S.R. AF 1.11.83 ApS | Company | 33.3% | 33.3% | 2019 |
FÆLLES INVEST 2 A/S | Company | 10.0% | 10.0% | 2018 |
ALSMARK INVEST II ApS | Company | 33.3% | 33.3% | 2014 |
LANC ApS | Company | 5.0% | 5.0% | 2014 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Alsium II ApS
MC2 Therapeutics A/S Board members of MC2 Therapeutics A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Trine Ahlgreen | Management | 0 companies |
| Anette Merete Nøhr Clausen | Management | 0 companies |
| Jesper Jørn Lange | Founder | 0 companies |
| Steen Sindet-Pedersen | Management | 0 companies |
| Mette Vagner Johannesen | Board of Directors | 0 companies |
| Tomas Dahl Mikkelsen | Board of Directors | 0 companies |
| Paul Louis Berns | Board of Directors | 0 companies |
| Anders Dahlgaard Hove | Board of Directors | 0 companies |
| John Sørensen Haurum | Board of Directors | 0 companies |
| Mads Jørgen Nøhr Clausen | Chairman | 0 companies |